Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TevaGastrim for Stem Cell Mobilization of HLA Matched Sibling Donors for Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Next Previous
Trial Profile

TevaGastrim for Stem Cell Mobilization of HLA Matched Sibling Donors for Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Stem cell mobilisation
  • Focus Therapeutic Use

Most Recent Events

  • 19 Apr 2016 Status changed from active, no longer recruiting to completed.
  • 01 Dec 2015 Planned End Date changed from 1 May 2014 to 1 May 2016 as reported by ClinicalTrials.gov record.
  • 01 Dec 2015 Planned primary completion date changed from 1 May 2014 to 1 May 2016 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top